User profiles for "author:L Thomassen"

Leen Thomassen

KU Leuven
Verified email at kuleuven.be
Cited by 4767

[HTML][HTML] The nanosilica hazard: another variable entity

D Napierska, LCJ Thomassen, D Lison… - Particle and fibre …, 2010 - Springer
Silica nanoparticles (SNPs) are produced on an industrial scale and are an addition to a
growing number of commercial products. SNPs also have great potential for a variety of …

Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969–1993

SO Dalton, L Mellemkjær, L Thomassen… - Schizophrenia …, 2005 - Elsevier
We investigated the cancer risk of patients hospitalized for schizophrenia in a nationwide
cohort study. All 22766 adults admitted for schizophrenia, ICD-8 295, in Denmark between …

Visual impairment in stroke patients–a review

KM Sand, A Midelfart, L Thomassen… - Acta Neurologica …, 2013 - Wiley Online Library
Approximately 30% of all stroke patients suffer from post‐stroke visual impairment.
Hemianopia is the most common symptom, but also neglect, diplopia, reduced visual acuity …

[HTML][HTML] Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke

…, JD Spence, L Thomassen - … England Journal of …, 2017 - Mass Medical Soc
Background The efficacy of closure of a patent foramen ovale (PFO) in the prevention of
recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO …

Size‐dependent cytotoxicity of monodisperse silica nanoparticles in human endothelial cells

D Napierska, LCJ Thomassen, V Rabolli, D Lison… - Small, 2009 - Wiley Online Library
The effect that monodisperse amorphous spherical silica particles of different sizes have on
the viability of endothelial cells (EAHY926 cell line) is investigated. The results indicate that …

Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

…, H Næss, U Waje-Andreassen, L Thomassen - The Lancet …, 2017 - thelancet.com
Background Tenecteplase is a newer thrombolytic agent with some pharmacological
advantages over alteplase. Previous phase 2 trials of tenecteplase in acute ischaemic stroke …

IL‐6: an early marker for outcome in acute ischemic stroke

…, J Kråkenes, E Ulvestad, L Thomassen… - Acta Neurologica …, 2005 - Wiley Online Library
Objectives–Inflammation plays an important role in the pathophysiology of stroke. We
correlated interleukin (IL)‐6, IL‐10, C‐reactive protein (CRP) and T‐lymphocyte subtype …

Etiology of first‐ever ischaemic stroke in European young adults: the 15 cities young stroke study

…, C Valcarenghi, L Thomassen… - European journal of …, 2013 - Wiley Online Library
Background and purpose Risk factors for IS in young adults differ between genders and
evolve with age, but data on the age‐and gender‐specific differences by stroke etiology are …

Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount

S Hussain, S Boland, A Baeza-Squiban, R Hamel… - Toxicology, 2009 - Elsevier
The ubiquitous presence of nanoparticles (NPs) together with increasing evidence linking
them to negative health effects points towards the need to develop the understanding of …

Aggregation and fibrillation of bovine serum albumin

NK Holm, SK Jespersen, LV Thomassen… - … et Biophysica Acta (BBA …, 2007 - Elsevier
The all-α helix multi-domain protein bovine serum albumin (BSA) aggregates at elevated
temperatures. Here we show that these thermal aggregates have amyloid properties. They …